Supplementary Materials

This PDF file includes:

  • Fig. S1. Neutralizing anti–TGF-β monoclonal antibody and SB431542 partially reverse the stabilized mesenchymal phenotype.
  • Fig. S2. Prolonged TGF-β treatment does not maintain the expression of TGF-β ligand.
  • Fig. S3. Prolonged TGF-β treatment stabilizes cell migration and invasion.
  • Fig. S4. Prolonged TGF-β treatment increases the resistance of breast cancer cells against 5-fluorouracil and paclitaxel.
  • Fig. S5. Histological evaluation of tumors from mice injected with HMLER cells.
  • Fig. S6. HMLER cells treated with TGF-β for 2 or 12 days maintain their TGF-β responsiveness.
  • Fig. S7. Quantification of the phosphorylation of mTOR targets and EMT marker expression.
  • Fig. S8. RapaLink-1 partially reduces the colony formation of untreated or short-term TGF-β–treated HMLER cells.
  • Table S1. Primer sequences used for quantitative real-time PCR.

[Download PDF]